Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTM-GDT
- Development stage
- Preclinical
- Lead developer
- CytoMed Therapeutics China
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous (inferred Based On Standard Practice For Adoptive Cell Therapies)
01
Overview
CTM-GDT is an allogeneic cell therapy product consisting of expanded gamma delta (γδ) T cells derived from healthy donors. Developed by CytoMed Therapeutics, the therapy leverages the unique properties of γδ T cells, which possess multiple antigen recognition systems and can recognize markers of cellular stress on cancer cells independent of HLA type. This enables them to target a broad range of cancers, including solid tumors and hematological malignancies. Unlike autologous therapies that use patient-derived cells, CTM-GDT provides an "off-the-shelf" source for consistent cytotoxic activity against tumors. The product is currently in preclinical and early clinical development for various cancer indications[1][3][4][5][6].
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on CTM-GDT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTM-GDT.